Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

Inclusion Criteria:

• Participants ≥ 18 years of age (or ≥ legal adult age within country if it is olderthan 18 years) at time of signing informed consent.

• Participants with histologically or cytologically confirmed ES-SCLC that progressedor recurred following at least one line of platinum-based anti-cancer therapy forSCLC.

Note: Participants with prior treatment for LS-SCLC should have also received another regimen for their recurrent, ES-SCLC disease.

• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.

• Participants must have adequate organ function (cardiac, pulmonary, kidney, andliver).

• Participants must be able to have SC injections administered in the abdomen.

• Participants without measurable disease or tumor tissue (fresh biopsy or archival)available may be permitted after discussion with and approval by Amgen MedicalMonitor.

Exclusion Criteria:

• Participants that have received prior DLL3 targeted therapy.

• Participants with untreated or symptomatic brain metastases or those requiringtherapy with steroids.

• Note: Participants with asymptomatic brain metastatic lesions are allowed followingdefinitive treatment (Amgen Medical Monitor may approve untreated, asymptomaticbrain metastasis if local therapy is not required per investigator judgment).

• Participants with leptomeningeal disease.

• Participants with baseline oxygen requirement.